Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970402 | 0.83 | SMN1; SMN2 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31095680 | 0.82 | KMT2A (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3933250 | 0.79 | LDHA (0.47) | KMT2AMEN1MAPTTSHRKDM4E | |
| SCHEMBL2084218 | 0.78 | TSHR (0.46) | CA1CA2CA9KMT2AMEN1 | |
| SCHEMBL3932726 | 0.77 | CXCR2 (0.50) | KMT2AMEN1KDM4EGAAGLA | |
| SCHEMBL3173889 | 0.75 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23462322 | 0.74 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6283230 | 0.73 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25469272 | 0.73 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23462371 | 0.73 | ABL1 (0.43) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642643-B2 | CXCR2 antagonists | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| EP-2041072-B1 | CXCR2 ANTAGONISTS | SANOFI SA (FR) | 2013-09-11 | — | — | EP | disclosed |
| US-20090258906-A1 | CXCR2 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2041072-A1 | CXCR2 ANTAGONISTS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000408-A1 | CXCR2 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258906-A1 | CXCR2 ANTAGONISTS | CXCR2, CXCR1, CXCR3 | CA12 2242/4885CA1 1631/4885CA2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.